{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:28:15Z","timestamp":1790677695598,"version":"4.1.0"},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>A meaningful part of schizophrenia patients suffer from physiosomatic symptoms\n(formerly named psychosomatic), which are reminiscent of chronic fatigue syndrome and fibromyalgia\n(FF) and are associated with signs of immune activation and increased levels of tryptophan\ncatabolites (TRYCATs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>The study aims to examine whether FF symptoms in schizophrenia are associated with the\nbreakdown of the paracellular pathway, zonulin, lowered natural IgM responses to oxidative specific\nepitopes (OSEs); and whether FF symptoms belong to the behavioral-cognitive-physical-psychosocial-\n(BCPS)-worsening index consisting of indices of a general cognitive decline (G-CoDe), symptomatome\nof schizophrenia, and quality of life (QoL)-phenomenome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>FF symptoms were assessed using the Fibromyalgia and Chronic Fatigue Rating scale in 80\nschizophrenia patients and 40 healthy controls and serum cytokines\/chemokines, IgA levels to TRYCATs,\nIgM to OSEs, zonulin and transcellular\/paracellular (TRANS\/PARA) molecules were assayed\nusing ELISA methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A large part (42.3%) of the variance in the total FF score was explained by the regression on\nthe PARA\/TRANS ratio, pro-inflammatory cytokines, IgM to zonulin, IgA to TRYCATs (all positively),\nand IgM to OSEs (inversely). There were highly significant correlations between the total FF\nscore and G-CoDe, symtopmatome, QoL phenomenome, and BCPS-worsening score. FF symptoms\nbelong to a common core shared by G-CoDe, symtopmatome, and QoL phenomenome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The physio-somatic symptoms of schizophrenia are driven by various pathways, including\nincreased zonulin, breakdown of the paracellular tight-junctions pathway, immune activation with\ninduction of the TRYCAT pathway, and consequent neurotoxicity. It is concluded that FF symptoms\nare part of the phenome of schizophrenia and BCPS-worsening as well.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1871527321666220806100600","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T02:32:15Z","timestamp":1660098735000},"page":"215-225","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["In Schizophrenia, Chronic Fatigue Syndrome- and Fibromyalgia-Like\nSymptoms are Driven by Breakdown of the Paracellular Pathway with\nIncreased Zonulin and Immune Activation-Associated Neurotoxicity"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2012-871X","authenticated-orcid":true,"given":"Michael","family":"Maes","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"},{"name":"Department of Psychiatry,\nMedical University of Plovdiv, Plovdiv, Bulgaria"},{"name":"IMPACT Strategic Research Center, Deakin University,\nGeelong, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Andr\u00e9s-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Group of Psychological Research in Fibromyalgia &amp; Chronic Pain (AGORA), Institut de Recerca\nSant Joan de D\u00e9u, Esplugues de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristo","family":"Vojdani","sequence":"additional","affiliation":[{"name":"Immunosciences Lab., Inc, Los Angeles, CA, USA"},{"name":"Cyrex Labs, LLC, Phoenix, AZ, USA"},{"name":"Department of Preventive Medicine, Loma Linda University, Loma Linda, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunee","family":"Sirivichayakul","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Decio S.","family":"Barbosa","sequence":"additional","affiliation":[{"name":"Health Sciences Graduate Program, Health Sciences Center, State University of Londrina, Londrina, PR, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buranee","family":"Kanchanatawan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1478-7954-8-24","volume":"8","author":"Phanthunane P.","year":"2010","unstructured":"Phanthunane P.; Vos T.; Whiteford H.; Bertram M.; Udomratn P.; Schizophrenia in Thailand: Prevalence and burden of disease. Popul Health Metr 2010,8,24","journal-title":"Popul Health Metr"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3390\/brainsci10090645","volume":"10","author":"Maes M.","year":"2020","unstructured":"Maes M.; Vojdani A.; Galecki P.; Kanchanatawan B.; How to construct a bottom-up nomothetic network model and disclose novel nosological classes by integrating risk resilience and adverse outcome pathways with the phenome of Schizophrenia. Brain Sci 2020,10(9),645","journal-title":"Brain Sci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1007\/s12035-020-02047-5","volume":"57","author":"Maes M.","year":"2020","unstructured":"Maes M.; Sirivichayakul S.; Matsumoto A.K.; Lowered antioxidant defenses and increased oxidative toxicity are hallmarks of deficit schizophrenia: A nomothetic network psychiatry approach. Mol Neurobiol 2020,57(11),4578-4597","journal-title":"Mol Neurobiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5498\/wjp.v11.i1.1","volume":"11","author":"Stoyanov D.","year":"2021","unstructured":"Stoyanov D.; Maes M.H.; How to construct neuroscience-informed psychiatric classification? Towards nomothetic networks psychiatry. World J Psychiatry 2021,11(1),1-12","journal-title":"World J Psychiatry"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852920001182","volume":"20","author":"Almulla A.F.","year":"2020","unstructured":"Almulla A.F.; Al-Hakeim H.K.; Maes M.; Schizophrenia phenomenology revisited: Positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity of schizophrenia. CNS Spectr 2020,20,1-10","journal-title":"CNS Spectr"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2174\/1568026620666200128143948","volume":"20","author":"Al-Hakeim H.K.","year":"2020","unstructured":"Al-Hakeim H.K.; Almulla A.F.; Al-Dujaili A.H.; Maes M.; Construction of a neuro-immune-cognitive pathway-phenotype underpinning the phenome of deficit Schizophrenia. Curr Top Med Chem 2020,20(9),747-758","journal-title":"Curr Top Med Chem"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852921000419","volume":"12","author":"Maes M.","year":"2021","unstructured":"Maes M.; Kanchanatawan B.; In (deficit) schizophrenia, a general cognitive decline partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life. CNS Spectr 2021,12,1-10","journal-title":"CNS Spectr"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11011-018-0339-7","volume":"34","author":"Kanchanatawan B.","year":"2019","unstructured":"Kanchanatawan B.; Sriswasdi S.; Maes M.; Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia. Metab Brain Dis 2019,34(1),267-282","journal-title":"Metab Brain Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1007\/s12035-021-02343-8","volume":"58","author":"Maes M.","year":"2021","unstructured":"Maes M.; Vojdani A.; Sirivichayakul S.; Barbosa D.S.; Kanchanatawan B.; Inflammatory and oxidative pathways are new drug targets in multiple episode schizophrenia and leaky gut, klebsiella pneumoniae, and C1q immune complexes are additional drug targets in first episode Schizophrenia. Mol Neurobiol 2021,58(7),3319-3334","journal-title":"Mol Neurobiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s11011-017-9982-7","volume":"32","author":"Kanchanatawan B.","year":"2017","unstructured":"Kanchanatawan B.; Sirivichayakul S.; Thika S.; Physio-somatic symptoms in schizophrenia: Association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway. Metab Brain Dis 2017,32(4),1003-1016","journal-title":"Metab Brain Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.schres.2020.05.003","volume":"222","author":"Almulla A.F.","year":"2020","unstructured":"Almulla A.F.; Al-Hakeim H.K.; Abed M.S.; Carvalho A.F.; Maes M.; Chronic fatigue and fibromyalgia symptoms are key components of deficit schizophrenia and are strongly associated with activated immune-inflammatory pathways. Schizophr Res 2020,222,342-353","journal-title":"Schizophr Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11011-020-00619-x","volume":"36","author":"Mousa R.F.","year":"2021","unstructured":"Mousa R.F.; Al-Hakeim H.K.; Alhaideri A.; Maes M.; Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: Neuro-immune and opioid system correlates. Metab Brain Dis 2021,36(1),169-183","journal-title":"Metab Brain Dis"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0022-3999(01)00315-4","volume":"52","author":"Zachrisson O.","year":"2002","unstructured":"Zachrisson O.; Regland B.; Jahreskog M.; Kron M.; Gottfries C.G.; A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). J Psychosom Res 2002,52(6),501-509","journal-title":"J Psychosom Res"},{"key":"ref=14","author":"Kittirathanapaiboon P.","year":"2005","unstructured":"Kittirathanapaiboon P.; Khamwongpin M.;  The Validity of the Mini International Neuropsychiatric Interview (MINI) Thai Version 2005","journal-title":"The Validity of the Mini International Neuropsychiatric Interview (MINI) Thai Version"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"Overall J.E.","year":"1962","unstructured":"Overall J.E.; Gorham D.R.; The brief psychiatric rating scale. Psychol Rep 1962,10,799-812","journal-title":"Psychol Rep"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1600-0447.1986.tb06276.x","volume":"74","author":"Kay S.R.","year":"1986","unstructured":"Kay S.R.; Fiszbein A.; Lindenmayer J.P.; Opler L.A.; Positive and negative syndromes in schizophrenia as a function of chronicity. Acta Psychiatr Scand 1986,74(5),507-518","journal-title":"Acta Psychiatr Scand"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1192\/S0007125000291496","volume":"7","author":"Andreasen N.C.","year":"1989","unstructured":"Andreasen N.C.; The scale for the assessment of negative symptoms (SANS): Conceptual and theoretical foundations. Br J Psychiatry Suppl 1989,7(7),49-58","journal-title":"Br J Psychiatry Suppl"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"Hamilton M.","year":"1960","unstructured":"Hamilton M.; A rating scale for depression. J Neurol Neurosurg Psychiatry 1960,23,56-62","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF00435734","volume":"2","year":"1993","unstructured":"Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res 1993,2(2),153-159","journal-title":"Qual Life Res"},{"key":"ref=20","year":"2018","unstructured":"The most validated cognitive research software CANTABAvailable from: 2018","journal-title":"The most validated cognitive research software"},{"key":"ref=21","year":"1986","unstructured":"CERAD \u2013 An overview: The consortium to establish a registry for Alzheimer\u2019s disease. Available from: 1986"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"7056","DOI":"10.1007\/s12035-019-1578-2","volume":"56","author":"Maes M.","year":"2019","unstructured":"Maes M.; Sirivichayakul S.; Kanchanatawan B.; Vodjani A.; Upregulation of the intestinal paracellular pathway with breakdown of tight and adherens junctions in deficit Schizophrenia. Mol Neurobiol 2019,56(10),7056-7073","journal-title":"Mol Neurobiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fpsyt.2013.00035","volume":"4","author":"Orellana G.","year":"2013","unstructured":"Orellana G.; Slachevsky A.; Executive functioning in schizophrenia. Front Psychiatry 2013,4,35","journal-title":"Front Psychiatry"},{"key":"ref=24","first-page":"401","volume":"41","author":"Orellana G.","year":"2013","unstructured":"Orellana G.; Alvarado L.; Mu&#xF1;oz-Neira C, &#xC1;vila R, M&#xE9;ndez MF, Slachevsky A. Psychosis-related matricide associated with a lesion of the ventromedial prefrontal cortex. J Am Acad Psychiatry Law 2013,41(3),401-406","journal-title":"J Am Acad Psychiatry Law"},{"key":"ref=25","first-page":"454","author":"Vojdani A.","year":"2019","unstructured":"Vojdani A.; Vojdani E.;  Food-Associated Autoimmunities: When Food Breaks Your Immune System 2019,454","journal-title":"Food-Associated Autoimmunities: When Food Breaks Your Immune System"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1007\/s12035-020-01961-y","volume":"57","author":"Rudzki L.","year":"2020","unstructured":"Rudzki L.; Maes M.; The Microbiota-Gut-Immune-Glia (MGIG) axis in major depression. Mol Neurobiol 2020,57(10),4269-4295","journal-title":"Mol Neurobiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-1781(01)00298-0","volume":"104","author":"Maes M.","year":"2001","unstructured":"Maes M.; Delanghe J.; Bocchio Chiavetto L.; Haptoglobin polymorphism and schizophrenia: Genetic variation on chromosome 16. Psychiatry Res 2001,104(1),1-9","journal-title":"Psychiatry Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-1781(96)02915-0","volume":"66","author":"Maes M.","year":"1997","unstructured":"Maes M.; Delange J.; Ranjan R.; Acute phase proteins in schizophrenia, mania and major depression: Modulation by psychotropic drugs. Psychiatry Res 1997,66(1),1-11","journal-title":"Psychiatry Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jad.2006.08.021","volume":"99","author":"Maes M.","year":"2007","unstructured":"Maes M.; Mihaylova I.; Leunis J.C.; Increased serum IgA and IgM against LPS of enterobacteria in Chronic Fatigue Syndrome (CFS): Indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability. J Affect Disord 2007,99(1-3),237-240","journal-title":"J Affect Disord"},{"key":"ref=30","first-page":"902","volume":"29","author":"Maes M.","year":"2008","unstructured":"Maes M.; Leunis J.C.; Normalization of leaky gut in Chronic Fatigue Syndrome (CFS) is accompanied by a clinical improvement: Effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. Neuroendocrinol Lett 2008,29(6),902-910","journal-title":"Neuroendocrinol Lett"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e85375","DOI":"10.1172\/jci.insight.85375","volume":"1","author":"Yang H.","year":"2016","unstructured":"Yang H.; Wang H.; Levine Y.A.; Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes. JCI Insight 2016,1(7),e85375","journal-title":"JCI Insight"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nri1594","volume":"5","author":"Lotze M.T.","year":"2005","unstructured":"Lotze M.T.; Tracey K.J.; High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005,5(4),331-342","journal-title":"Nat Rev Immunol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12974-016-0670-z","volume":"13","author":"Festoff B.W.","year":"2016","unstructured":"Festoff B.W.; Sajja R.K.; van Dreden P.; Cucullo L.; HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer\u2019s disease. J Neuroinflammation 2016,13(1),194","journal-title":"J Neuroinflammation"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/schbul\/sbaa136","volume":"47","author":"Al-Dujaili A.H.","year":"2021","unstructured":"Al-Dujaili A.H.; Mousa R.F.; Al-Hakeim H.K.; Maes M.; High mobility group protein 1 and dickkopf-related protein 1 in Schizophrenia and treatment-resistant Schizophrenia: Associations with interleukin-6, symptom domains, and neurocognitive impairments. Schizophr Bull 2021,47(2),530-541","journal-title":"Schizophr Bull"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/1741-7015-11-205","volume":"11","author":"Morris G.","year":"2013","unstructured":"Morris G.; Maes M.; Myalgic encephalomyelitis\/chronic fatigue syndrome and encephalomyelitis disseminata\/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med 2013,11,205","journal-title":"BMC Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1007\/s12035-020-01939-w","volume":"57","year":"2020","unstructured":"Bj&#xF8;rklund G, Dadar M, Pivina L, Do&#x15F;a MD, Semenova Y, Maes M. Environmental, neuro-immune, and neuro-oxidative stress interactions in chronic fatigue syndrome. Mol Neurobiol 2020,57(11),4598-4607","journal-title":"Mol Neurobiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/diagnostics11010095","volume":"11","author":"Stoyanov D.","year":"2021","unstructured":"Stoyanov D.; Aryutova K.; Kandilarova S.; Diagnostic task specific activations in functional MRI and aberrant connectivity of insula with middle frontal gyrus can inform the differential diagnosis of psychosis. Diagnostics (Basel) 2021,11(1),95","journal-title":"Diagnostics (Basel)"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527321666220806100600","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/207326\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527321666220806100600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T07:52:41Z","timestamp":1676533961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/207326\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527321666220806100600","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.05.09.21256897","asserted-by":"object"}]},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}